Corona Remedies made a remarkable debut on the stock market, opening with a significant premium. The company’s Rs 655-crore IPO was massively oversubscribed, attracting strong interest from institutional and retail investors alike. This robust demand reflects confidence in Corona Remedies’ solid financial performance, strategic focus on key healthcare areas, and promising earnings potential.